Illustration — photo to followLot AV-TIR-2609-A
Tirzepatide
Peptide pen · 30 mg / 3 mL
VAT included · 1 pen · 30 mg / 3 mL
Sold for research use only. Not a medicine and not authorised for human consumption. Purchasers must be 18+ and confirm intended use at checkout.
Authorised as a medicine elsewhere (United Kingdom, United States, European Union, Australia and Canada) — this pen is a research product, not the licensed medicine.
- Ships chilled · same-day dispatch before 2 pm
- Free UK shipping over £300
About
What this is
Tirzepatide is included in the guide under metabolic & weight. The reference focuses on gip and glp-1 signalling, appetite and metabolic outcomes and distinguishes biological rationale from demonstrated outcomes. Supplied by the manufacturer as a pre-filled 30 mg / 3 mL dose-dial pen for research use — no reconstitution, no vials, no drawing up. Our evidence record is linked below and graded on the same scale as every compound on this site.
- 01Pre-filled pen — no reconstitution
- 02Identity confirmed by LC-MS per lot
- 03Purity ≥ 99% by HPLC
- 04Certificate published against the lot number
Specification
What's in the pen
Device
How the pen works
- 01
Attach a pen needle
Take the cap off, wipe the septum with an alcohol swab and screw a compatible pen needle on until it seats. Use a fresh needle every time and never share a pen.
- 02
Prime
Dial a small test amount, hold the pen needle-up and press the button until a drop appears at the tip. This clears air from the needle and confirms the pen delivers.
- 03
Dial
Turn the dial to the volume you intend to deliver; the window shows the setting in the pen's increments. The dial sets a volume of solution — nothing more.
- 04
Inject
Insert as the pen-needle instructions describe, press the button fully and hold for ten seconds before withdrawing. Remove and bin the needle in a sharps container, recap and refrigerate.
Dosing is not provided; see the research information in the evidence record. These steps describe how the device operates, not how or whether to use its contents.
Certificate of analysis
Lot AV-TIR-2609-A
Independent test of a sample from lot AV-TIR-2609-A of Tirzepatide. Testing confirms what is in the pen and how pure it is; it does not speak to safety or effect in people. How we test
Evidence record · reviewed 1 Sept 2026
What the research says about Tirzepatide
Once-weekly dual incretin with the largest weight loss among authorised medicines.
- Overall evidence
- Strong
- Human evidence
- Approved medicine (for specific indications)
- Regulatory · jurisdictions on record
- Authorised
- Authorised · United Kingdom, United States, European Union, Australia and Canada
- United Kingdom · Authorised (MHRA) for type 2 diabetes and weight management (Mounjaro); prescription-only. · reviewed 1 Sept 2026
- Anti-doping · WADA
- Not on the Prohibited List
Fit
Who this is for
Weight management where the dual GIP/GLP-1 agonist with the largest weight reductions in trials is the interest.
- Significant weight to lose
- Wanting the compound with the largest trial weight loss
- Metabolic health alongside weight
Check your fit
The Peptide Checkup maps your goal and history against the evidence for this pen and tells you if it is a poor fit — even after you have bought it.
Check your fit · 7 minutesAlso in the range · by shared goal, then bestsellers
5 related pens
- Illustration — photo to follow
Semaglutide
Peptide pen · 10 mg / 3 mL
£265 
Tesamorelin
Peptide pen · 20 mg / 3 mL
£255
Retatrutide (R3T)
Peptide pen · 40 mg / 3 mL
£370- Illustration — photo to follow
CagriSema
Cagrilintide + semaglutide · 20 mg / 3 mL
£360 - Illustration — photo to follow
Liraglutide
Peptide pen · 18 mg / 3 mL
£235